NCT04730427View on ClinicalTrials.gov

Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19

PHASE1TerminatedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

March 24, 2021

Primary Completion Date

May 8, 2022

Study Completion Date

July 7, 2022

Conditions

Covid19

Interventions

DRUG

GX-I7

Recombinant human interleukin-7 hybrid Fc

DRUG

GX-I7 vehicle

Formulation buffer of recombinant human interleukin-7 hybrid Fc

Trial Locations (1)

07061

Borame Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Genexine, Inc.

INDUSTRY

NCT04730427 - Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19 | Biotech Hunter | Biotech Hunter